AbbVie Inc AbbVie (NYSE: ABBV) Announces FDA Extended Review Period for Upadacitinib’s NDA AbbVie Inc. (NYSE: ABBV) declared that FDA has made the decision regarding the supplemental New Drug Application (sNDA) for upadacitinib. FDA has decided that it will extend the review period for sNDA for upadacitinib.